Sponsor:
Filipa Lynce, MD
Code:
NCT06351332
Conditions
Breast Cancer
Breast Cancer Female
Triple Negative Breast Cancer
Hormone Receptor Negative Malignant Tumor Breast Triple
HER2-negative Breast Cancer
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Azenosertib
Carboplatin
Pembrolizumab
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Filipa Lynce, MD on 2024-12-18.